Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

Biohaven Ltd.

Biohaven Ltd.

BHVN

0.00

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE: BHVN) with a Overweight and raises the price target from $18 to $19.